CAN-FITE Sees Longer-Than-Expected Survival in Phase III Liver Cancer Trial
Israeli biotech reports a $4.6 million half-year loss and says blinded survival in its pivotal Namodenoson HCC study is running longer than assumed.
Israeli biotech reports a $4.6 million half-year loss and says blinded survival in its pivotal Namodenoson HCC study is running longer than assumed.
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.